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Abstract
Background: Ischemia and reperfusion (I/R) is one of the major causes of acute kidney injury (AKI). Citrate reduces
hypoxia-induced mitochondrial energetic deficits in isolated proximal tubules. Moreover, citrate anticoagulation is
now frequently used in renal replacement therapy. In the present study a rat model of I/R-induced AKI was utilized
to examine renal protection by citrate in vivo.
Methods: AKI was induced by bilateral renal clamping (40 min) followed by reperfusion (3 h). Citrate was infused at
three different concentrations (0.3 mmol/kg/h; 0.6 mmol/kg/h and 1.0 mmol/kg/h) continuously for 60 min before
and 45 min after ischemia. Plasma calcium concentrations were kept stable by infusion of calcium gluconate. The
effect of citrate was evaluated by biomonitoring, blood and plasma parameters, histopathology and tissue ATP
content.
Results: In comparison to the normoxic control group bilateral renal ischemia led to an increase of creatinine and
lactate dehydrogenase activity and a decrease in tissue ATP content and was accompanied by a drop in mean
arterial blood pressure. Infusion of 1.0 mmol/kg/h citrate led to lower creatinine and reduced LDH activity compared to
the I/R control group and a tendency for higher tissue ATP content. Pre-ischemic infusion of 1.0 mmol/kg/h citrate
stabilized blood pressure during ischemia.
Conclusions: Citrate has a protective effect during I/R-induced AKI, possibly by limiting the mitochondrial deficit as
well as by beneficial cardiovascular effects. This strengthens the rationale of using citrate in continuous renal replacement
therapy and encourages consideration of citrate infusion as a therapeutic treatment for AKI in humans.
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Background
Acute kidney injury (AKI) is still a life threatening dis-
ease. The application of uniform definitions and classifi-
cations during the past few years has shown that even
minor forms of AKI documented by minimal and totally
reversible rises in plasma creatinine are accompanied by
decreased patient survival and progression of chronic
kidney disease [1, 2]. AKI affects patients of various
medical disciplines, for example during sepsis or follow-
ing surgery with ischemia characterized by a shortage in
oxygen and nutrition supply being its major cause [3]. It
particularly occurs in critically ill patients, e.g. after heart
surgery and liver transplantation with an incidence of up
to 50% [4].
Despite substantial progress in medicine in general,
supportive treatment is still the only therapeutic strategy
in AKI. Renal replacement therapy is one of the major
options in severe cases of AKI. Kidney Disease Improv-
ing Global Outcomes (KDIGO) guidelines suggest the
use of regional citrate anticoagulation instead of heparin
in patients with AKI receiving continuous renal replace-
ment therapy [5]. This suggestion is not only based on
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superior filter longevity [6, 7], but also due to a reduction
in bleeding risks accompanied by regional anticoagulation
limited to the extracorporeal circuit [7–9]. Citrate anticoa-
gulation can lead to a number of metabolic complications
(acidosis, alkalosis, hypernatremia, hypocalcemia) and
should therefore only be used in centers providing the ne-
cessary expertise. However, incorporating a locally adapted
protocol and adequate metabolic biomonitoring especially
including ionized calcium levels during treatment citrate
anticoagulation can safely be used even in patients after
liver transplantation [10].
In addition to increased filter longevity and decreased
bleeding risks there are suggestions of direct advantages
from citrate application. Citrate may suppress inflamma-
tion [9, 11] and addition of citric acid cycle metabolites
including citrate itself during hypoxia and/or reoxygena-
tion to isolated proximal renal tubules improves ener-
getic function and recovery by driving substrate-level
phosphorylation that lowers accumulated non-esterified
fatty acids [12, 13]. We recently introduced a novel rodent
based animal model for studying ischemia/reperfusion (I/R)
AKI in vivo that incorporates intensive biomonitoring dur-
ing the ischemic and early postischemic periods. Using the
system we found that infusion of a substrate combination
of α-ketoglutarate plus malate that was highly protective in
vitro aggravated hypotension during ischemia and was not
protective in vivo [14]. The methodology developed for the
latter study lends itself to assessment of citrate effects since
it allows for the infusion and monitoring that are neces-
sary to employ citrate in the clinical setting. In the present
studies we have used the approach to examine whether
citrate provides renal protection in vivo.
Methods
Chemicals/Materials
Hematoxylin, ß-NADH, citrate lyse, L-lactic dehydrogen-
ase, malic dehydrogenase, triethanolamine and citrate were
obtained from Sigma-Aldrich (Steinheim, Germany). For-
malin solution (4.5% and 10%, buffered) and isoflurane
(Forene) were from Abbott (Wiesbaden, Germany), keta-
mine 10% was from Ceva (Düsseldorf, Germany), lidocaine
(Xylocaine 1%) from AstraZeneca (Wedel, Germany),
Ringer’s solution Macoflex N from MacoPharma Inter-
national (Langen, Germany), 0.9% NaCl solution and sterile
water (Aqua Ecotainer) were from Braun (Melsungen,
Germany), paraffin (Paraplast Tissue Embedding Medium
REF 501006) was from McCormick Scientific (St. Louis,
MO), medical oxygen from Air Liquide (Düsseldorf,
Germany) and heparin-sodium 25000 from Ratiopharm
GmbH (Ulm, Germany). Triton X-100, zinc chloride, am-
monium sulfate and magnesium sulfate were purchased
from AppliChem (Darmstadt, Germany), Tris from Serva
Electrophoresis (Heidelberg, Germany), Dulbecco’s Phos-
phate Buffered Saline (DPBS) from Invitrogen (Darmstadt,
Germany) and EDTA from Merck (Darmstadt, Germany).
Syringe pumps (Perfusor-Secura FT) were from Braun
(Melsungen, Germany), portex catheters (0.58 mm i.d.,
0.96 mm o.d.) from Smiths Medical International (Hythe,
U.K.), 4–0 Vicryl sutures from Ethicon (Norderstedt,
Germany), 2-ml syringes (Pico50) from Radiometer Med-
ical (Brønshøj, Denmark), safe-lock tubes (2 ml) from
Eppendorf (Hamburg, Germany) and 15 ml polypropylene
tubes (Falcon tubes) from BD Biosciences (Heidelberg,
Germany).
Animals
Male Sprague Dawley rats (390–490 g) were obtained
from Charles River (Sulzfeld, Germany). Animals were
kept for at least one week prior to the experiments in the
central animal unit of the University Hospital Essen under
standardized conditions of temperature (22 ± 1 °C), hu-
midity (55 ± 5%) and 12 h/12 h light/dark cycles with free
access to food (ssniff-Spezialdiäten, Soest, Germany) and
water; animals were not fasted prior to the experimental
procedures.
Anesthesia, analgesia and surgical procedure
Anesthesia with isoflurane and analgesia with ketamine
was performed as described previously [14, 15]. A skin-
deep incision was made along the thigh of both hind
limbs after application of lidocaine (5 mg/kg s.c.). Portex
catheters were placed in the exposed right femoral artery
and both femoral veins as well as in the urinary bladder
and fixed with 4–0 Vicryl ligatures. Following this pro-
cedure, a median abdominal laparotomy was performed
along the Linea alba. After an acclimation period of
30 min and the first infusion period (60 min) the intes-
tine was carefully evacuated from the abdominal cavity
and both kidneys were localized. The vascular pedicle of
each kidney was mobilized. In animals undergoing
clamping both renal pedicles were occluded for 40 min
using atraumatic mini-bulldogs (Aesculap, Tuttlingen,
Germany). The intestine was replaced into the abdom-
inal cavity and covered with moistened compresses and
aluminum foil to minimize evaporation and cooling.
Subsequent to the ischemic period of 40 min the
microvascular clamps were removed and the kidneys
thus reperfused. At the end of the reperfusion period of
180 min, including a second infusion period (45 min)
the right kidney was removed. A catheter was placed in
the abdominal aorta and the left kidney perfused at
100 mmHg with 40 ml isotonic NaCl solution containing
1500 I.U. heparin-sodium before being resected. Animals
remained anesthetized during the whole experiment and
were sacrificed by cardiac incision under deep isoflurane
anesthesia.
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Study groups
The protocols used are diagrammed in Fig. 1. The initial
animal study was performed with six rats per group. The
following experimental groups were compared:
– Group 1: normoxic control group, sham-operation,
0.9% NaCl;
– Group 2: I/R control group, 40 min renal clamping,
0.9% NaCl;
– Group 3: I/R citrate group, 40 min renal clamping,
citrate 0.3 mmol/kg/h (cumulative dose of citrate
0.525 mmol/kg ≈ 0.154 g/kg);
– Group 4: I/R citrate group, 40 min renal clamping,
citrate 0.6 mmol/kg/h (cumulative dose of citrate
1.05 mmol/kg ≈ 0.309 g/kg);
– Group 5: I/R citrate group, 40 min renal clamping,
citrate 1.0 mmol/kg/h (cumulative dose of citrate
1.75 mmol/kg ≈ 0.515 g/kg).
Citrate for all groups where it was used was adminis-
tered for 60 min prior to the clamp and during the first
45 min of reperfusion. The dose of citrate studied was
based on the use of the average dose for patients in the
University Hospital Essen who receive about 0.6 mmol/
kg/h citrate for anticoagulation during continuous renal
replacement therapy [10]. As the amount of citrate elim-
inated in continuous veno-venous hemodialysis is up to
50%, the amount of citrate reaching patients circulation
is most likely only about 0.3 mmol/kg/h.
The ischemic control group and the normoxic control
group of rats undergoing all surgical procedures except
clamping of the renal pedicles received only 0.9% NaCl
solution at a rate of 5 ml/kg/h during the experimental
period.
Citrate solutions were prepared from sterile 30% triso-
dium citrate solution (pH 4.84) available for regional
anticoagulation at the University Hospital Essen (Phar-
macy, University Hospital Essen). Sterile 30% trisodium
citrate solution was freshly dissolved in bidistilled water
to obtain final solutions containing
a) 0.3 mmol citrate/3 ml (0.401 ml 30% trisodium
citrate solution plus 2.599 ml bidistilled water);
b) 0.6 mmol citrate/3 ml (0.802 ml 30% trisodium
citrate solution plus 2.198 ml bidistilled water);
c) 1.0 mmol citrate/3 ml (1.337 ml 30% trisodium
citrate solution plus 1.663 ml bidistilled water).
Citrate solutions were filtered through a bacteria-tight
filter (Minisart 0.2 μm; Sartorius, Göttingen, Germany)
and infused with a syringe pump into the right V. femor-
alis at a rate of 3 ml/kg/h 60 min prior and 45 min after
ischemia. As in the clinical setting, pH was not adjusted.
There was no effect in any group of citrate infusion on
arterial pH at the end of the initial infusion period be-
fore ischemia (not shown).
Corresponding Ca2+-solutions needed to ensure
stable Ca2+ levels were based on 10% calcium gluco-
nate pH 5.5–7.5 (B. Braun, Melsungen, Germany) and
contained
a) for animals receiving 0.3 mmol/kg/h citrate:
0.136 mmol Ca2+/2 ml (0.6 ml 10% calcium
gluconate plus 1.4 ml bidistilled water);
Fig. 1 Experimental design. Infusions through each catheter during each experimental period are indicated. Both renal pedicles were
atraumatically clamped during the 40 min ischemic period. In the initial study, the dose of trisodium citrate administered pre-ischemia for
60 min and during the first 45 min of reperfusion was 0.3, 0.6 or 1.0 mmol/kg/h at a rate of 5 ml/kg/h. In the normoxic and I/R control
groups, 0.9% NaCl solution was infused instead at the same rates. In a follow-up study, 1.0 mmol/kg/h trisodium citrate was compared to
3.0 mmol/kg/h NaCl delivered as a 3.5% solution. Calcium gluconate solutions were administered at 2 ml/kg/h. [cross black], blood sampling,
[cross white], urine sampling. Blood pressure, heart rate, respiratory rate, core body temperature, and peripheral oxygen saturation were continuously
monitored during the entire experiment
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b) for animals receiving 0.6 mmol/kg/h citrate:
0.271 mmol Ca2+/2 ml (1.2 ml 10% calcium
gluconate plus 0.8 ml bidistilled water);
c) for animals receiving 1.0 mmol/kg/h citrate:
0.452 mmol Ca2+/2 ml (undiluted 10% calcium
gluconate).
Calcium gluconate solutions were filtered through a
bacteria-tight filter (Minisart 0.2 μm; Sartorius, Göttingen,
Germany) and infused with a with a syringe pump into the
left V. femoralis at a rate of 2 ml/kg/h. As in the clinical set-
ting, pH was not adjusted. Infusion of calcium gluconate
was started 10 min prior to infusion of citrate solutions and
was continued throughout ischemia and during the first
80 min of reperfusion. Calcium gluconate dosage and infu-
sion time were determined empirically in pilot studies.
After the initial results indicated hemodynamic benefit
of citrate a follow-up study was then performed to con-
trol for citrate-independent effects of the Na+ load that
accompanies citrate. This study consisted of:
– Group I: normoxic control group, sham-operation,
0.9% NaCl ≈ 0.77 mmol/kg/h Na+ (three rats);
– Group II: I/R control group, 40 min renal clamping,
0.9% NaCl ≈ 0.77 mmol/kg/h Na+ (four rats);
– Group III: I/R citrate group, 40 min renal clamping,
citrate 1.0 mmol/kg/h (including 3.0 mmol/kg/h Na+)
(cumulative dose of citrate 1.75 mmol/kg ≈ 0.515 g/kg)
(six rats);
– Group IV: I/R high sodium group, 40 min renal
clamping, 3.5% NaCl ≈Na+ 3.0 mmol/kg/h (six rats).
As in the initial study animals of the I/R citrate
1.0 mmol/kg/h group received undiluted 10% calcium
gluconate during time span indicated above.
Summarizing both experimental studies, three animals
died due to cardiac arrest during acclimation/before in-
duction of ischemia and catheter placement failed in two
rats. Those five animals were replaced. Therefore, all an-
imals exposed to ischemia were included in the final
analysis.
Monitoring of vital parameters
Vital parameters were assessed every 10 min starting
with the beginning of the surgical procedure (Fig. 1).
Systolic, diastolic and mean arterial blood pressures were
continuously recorded via the femoral artery catheter
that was connected with a pressure transducer (MX 960;
Medex Medical, Rossendale, UK). An infusion bag con-
taining Ringer’s solution delivered 3 ml/h to keep the
catheter functional. At a mean arterial blood pressure
below 70 mmHg for more than 5 min, bolus injections
of 0.5 ml 0.9% NaCl solution were administered repeti-
tively through the right femoral artery catheter up to a
maximum volume of 5 ml/kg/h. Rat heart rates were de-
termined from systolic blood pressure spikes. The core
body temperature of the rats was continuously monitored
using a rectal sensor and maintained at 37.6 ± 0.2 °C by
means of an underlying thermostated operating table and
by coverage with aluminum foil. The breathing rate was
determined based on ventilation movements in 10-min
intervals.
Urine containers were changed after 30 min, immedi-
ately before ischemia, after 40 min of ischemia, after 45,
120 and 180 min of reperfusion (Fig. 1).
Assessment of blood and plasma parameters
Using a 2-ml syringe containing 80 I.U. electrolyte-
balanced heparin, blood samples (0.5 ml) were taken
from the femoral artery catheter immediately after its in-
sertion, after 30 min, immediately before ischemia, after
40 min of ischemia, after 45 min, and after 180 min of
reperfusion (Fig. 1). For each blood sample animals were
replaced with 0.5 ml 0.9% NaCl solution via the femoral
artery. For determination of arterial oxygen and PCO2,
oxygen saturation, pH, acid–base status, hemoglobin
concentration and hematocrit, electrolytes (Na+, K+, Cl−,
Ca2+), metabolic parameters (lactate, glucose) and osmo-
lality, a blood gas analyzer equipped with additional
electrodes was used (ABL 715; Radiometer, Copenhagen,
Denmark).
Blood plasma was obtained by centrifugation (3,000 × g
for 15 min at 25 °C) and stored at 4 °C until its use (within
4 h). The plasma activity of lactate dehydrogenase (LDH)
served as a general indicator of cell injury, while plasma
creatinine (pCrea) was measured as an indicator for AKI.
Plasma levels were determined spectrophotometrically by
a fully automated clinical chemistry analyzer (Vitalab
Selectra E; VWR International, Darmstadt, Germany).
Determination of tissue ATP
The caudal poles of both kidneys were cut off at the end
of reperfusion, immediately before kidney removal,
stored in safe-lock tubes (2 ml) containing 1 M perchlo-
ric acid in an extracellular buffer for deproteinization
[16], were mixed vigorously and immediately frozen in
liquid nitrogen. Samples were kept frozen at −80 °C. Tis-
sue ATP content was measured using a luciferase-driven
bioluminescence assay (ATP Bioluminescence Assay Kit
CLS II, Roche, Mannheim, Germany). After thawing,
samples were diluted in buffer containing 100 mM Tris
and 4 mM EDTA (pH 7.75) and mixed immediately
with luciferase reagent. Light emission was detected at
550 nm by a luminometer (Berthold Detection Systems,
Pforzheim, Germany). ATP content was normalized for
tissue protein content as determined according to
Lowry [17].
Bienholz et al. BMC Nephrology  (2017) 18:130 Page 4 of 14
Histopathological evaluation of the ischemia-reperfusion
injury of the kidney
For histological examination the left blood-free kidney
was sliced in half and fixed in formalin (10%, neutral
buffered) for 24–48 h. Afterwards, it was embedded in
paraffin and cut on a rotary microtome in serial sections
of 2 μm thickness. Tissue sections were mounted on
slides and stained with hematoxylin-eosin. Histopatho-
logical changes were evaluated in a blinded fashion
based on the following criteria: 1. Blood content in
glomeruli; 2. shrunken or swollen glomeruli; 3. loss of
brush border; 4. shrunken or swollen tubular epithelial
cells; 5. intraluminal casts and 6. indicators of cell death
(loss of nuclei).
Determination of citrate in plasma and urine
Citrate was enzymatically converted into ß-NAD which
was detected at 37 °C with a Hitachi F-2500 fluorescence
spectrophotometer (Düsseldorf, Germany) (emission:
471 nm; absorption: 353 nm).
In detail, 1 ml assay buffer (50 mM triethanolamine,
10 mM MgSO4, 5 mM EDTA, 8.340 ml/l L-lactic de-
hydrogenase, 1.628 ml/l malic dehydrogenase, pH = 7.4)
was incubated in cuvettes in a light protected water
bath (Lauda ecoline 003 with thermostat E100, Lauda-
Königshofen, Germany) for 10 min. 10 μl citrate stand-
ard and samples were added to the cuvettes with
10 min of further incubation. Subsequently, baseline
emission was measured. Immediately after the measure-
ment 10 μl citrate lyse enzyme solution (32.6 g/l citrate
lyse, 10 mM triethanolamine, 0.3 mM zinc chloride,
545 mM ammonium sulphate) was added. Emission was
measured again following 60 min of incubation.
Determination of plasma osmolality by cryoscopy
Plasma osmolality was directly determined by cryoscopy
using an electronic semi-micro osmometer (Typ M,
Knauer, Berlin, Germany).
In order to avoid excess amounts of blood sampling
that could affect the experimental outcome, changes of
osmolality were assessed in a separate study comparing
three animals per group.
– Group I (treatment analog Group 2): I/R control
group, 40 min renal clamping, 0.9% NaCl;
– Group II (treatment analog Group 5): I/R citrate
group, 40 min renal clamping, citrate 1.0 mmol/kg/h
(cumulative dose of citrate 1.75 mmol/kg ≈ 0.515 g/kg).
Animals underwent the exact same treatment as de-
scribed above including biomonitoring without acquire-
ment of blood samples except for two time points: 1.
directly before ischemia following the first 60 min of cit-
rate infusion; 2. after 100 min of reperfusion, as animals
undergoing ischemia and receiving 1.0 mmol/kg/h cit-
rate showed a peak in blood pressure at this time point
in the initial experimental study.
Statistics
Experiments were performed with six animals per ex-
perimental group unless indicated otherwise. Biochem-
ical assays were run at least in duplicate. Data are
expressed as mean values ± standard error of the mean.
Comparisons among multiple groups were performed
using analyses of variances either for nonrecurring or for
repeated measures (analysis over time) or Kruskal-Wallis
test followed by Bonferroni or Dunns post-hoc analysis.
A p-value < 0.05 was considered significant.
Results
Effects of citrate on markers of organ injury and tissue
ATP content
In the normoxic control group the pCrea and plasma
LDH concentrations remained stable throughout the ex-
periment. Kidney I/R resulted in an increase in pCrea
and LDH concentrations (Fig. 2ab). Tissue ATP content
was significantly decreased after I/R compared to the
normoxic control group (p < 0.01; Fig. 2c).
Infusion of citrate had no effects on pre-ischemic
values of all parameters (data not shown). Significant dif-
ferences after citrate infusion compared to the I/R con-
trol group were detected in the 1.0 mmol/kg/h citrate
group. In the 1.0 mmol/kg/h citrate group pCrea and
LDH levels were significantly less increased after 180 min
of reperfusion (p < 0.01 and p < 0.05), while tissue ATP
content tended also to be higher in the 1.0 mmol/kg/h
citrate group without reaching statistical significance
(Fig. 2c).
In the follow-up study performed to control for
citrate-independent effects of the high Na+ load that ac-
companies citrate, results for the 1.0 mmol/kg/h citrate
group were confirmed, while infusion of 3.0 mmol/kg/h
Na+ did not result in a significantly blunt the increase of
pCrea levels after 180 min of reperfusion compared to
the I/R control group (Fig. 3).
Effects of citrate on histopathological changes
I/R resulted in loss of brush border, increased numbers
of shrunken tubular epithelial cells and glomeruli as well
as formation of intraluminal casts. No difference in
histologic architecture could be detected between the I/R
control group and any citrate group at this relatively short
reperfusion period (not shown).
Effects of citrate on blood pressure and other vital
parameters
Baseline values of mean arterial blood pressure of all
animals were around 85 mmHg after the acclimation
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period. In the normoxic control group, MAP slowly
decreased over the course of the experiment and was
78 ± 3 mmHg (p = 0.02 vs. baseline) at the end of the
reperfusion period. In the I/R control group, blood
pressure rapidly decreased upon renal clamping showing
significant difference to the MAP of the normoxic control
group at 30 min (p < 0.05) and 40 min (p < 0.01) of is-
chemia (Fig. 4). During very early reperfusion, MAP of
the I/R control group tended to be higher compared to
the normoxic control group, but values of both groups
converged during the course of the experiment. Pre-
ischemic infusion of citrate had no immediate effect on
MAP, but increased blood pressure during renal clamping
in a concentration dependent manner, reaching statistical




Fig. 2 Creatinine, lactate dehydrogenase and ATP levels at the end
of reperfusion. Box plots with whiskers indicating minimum and
maximum, six rats per group. a Creatinine after 40 min of ischemia
plus 180 min of reperfusion. All I/R groups were significantly different
from the normoxic control group at p < 0.001. ** p < 0.01 vs. I/R control
group. b Lactate dehydrogenase (LDH) after 40 min of ischemia plus
180 min of reperfusion. ## p < 0.01 and ### p < 0.001 vs. normoxic
control group. ** p < 0.01 vs. I/R control group. c Tissue ATP content
after 40 min of ischemia plus 180 min of reperfusion. # p < 0.05
and ## p < 0.01 vs. normoxic control group. No significant
differences between 1.0 mmol/kg/h citrate and normoxic or I/R
control groups
Fig. 3 Creatinine levels for the follow-up study. The follow-up study
using the same design as the initial study (see Fig. 1) was conducted
to control for the citrate-independent effects of the sodium load that
accompanies citrate. Box plots with whiskers indication minimum and
maximum, 3–4 rats for the normoxic and I/R control groups and 6 rats
per group for the 1.0 mmol/kg/h citrate and 3.0 mmol/kg/h Na+
groups. Creatinine after 40 min of ischemia plus 180 min of reperfusion.
All I/R groups were significantly different from the normoxic control
group at p < 0.001. ** p < 0.01 vs. I/R control group
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comparison to the I/R control group at 30 min and
40 min of ischemia (p < 0.01, Fig. 4b). Upon reperfusion,
values of all experimental groups gradually normalized to
those of the normoxic control group, but MAP of the
1.0 mmol/kg/h citrate group tended to be higher during
most of the reperfusion period (Fig. 4a).
Consistent with the effects of intravenous citrate on
MAP during kidney ischemia, animals of the I/R control
group received significantly more bolus injections of 0.9%
NaCl solution than rats of the 1.0 mmol/kg/h group during
ischemia and reperfusion (1 bolus injection = 0.5 ml)
(2.5 ± 0.8 vs. 0.0 ± 0.0 and 2.7 ± 0.9 vs. 0.17 ± 0.17; p < 0.01)
(Fig. 5).
Heart rates showed high inter-individual difference
with no statistical difference between experimental groups.
Respiratory rate and core body temperature were not
significantly changed by kidney I/R in the absence or
presence of citrate in any dosage.
While infusion of citrate increased blood pressure dur-
ing renal clamping in a concentration dependent manner,
Fig. 4 Mean arterial blood pressure. Mean arterial blood pressure was assessed every 10 min starting with the beginning of the surgical
procedure. Arterial blood pressure was continuously recorded via a catheter placed in the femoral artery. Grey-shaded areas indicate the periods
of infusion of trisodium citrate at indicated concentrations. Calcium levels were kept stable by corresponding infusions of calcium gluconate
Normoxic and I/R control groups received only 0.9% NaCl solution. Infusion volume was 5 ml/kg/h in all animals. Values are means of six rats
per group. For other experimental details see Fig. 1. a Mean arterial blood pressure of all experimental groups. b Mean arterial blood pressure
of control groups and 1.0 mmol/kg/h citrate group. # p < 0.05 and ## p < 0.01 vs. normoxic control group. ** p < 0.01 vs. I/R control group
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this effect was not reproduced by concentrated NaCl in
the follow-up study performed to control for citrate-
independent effects of the Na+ load that accompanies
citrate (Fig. 6).
Effects of citrate on blood pH, PCO2, base excess,
electrolytes, and metabolic parameters
Table 1 summarizes values at baseline and at the end of
the experiment. In the normoxic control group glucose
and potassium levels slightly decreased over time, but
remained within the physiological range. All other pa-
rameters in the normoxic control group were stable dur-
ing the course of the experiment. Kidney I/R resulted in
a significantly lower base excess and significantly higher
potassium levels during reperfusion. No significant dif-
ferences in other electrolytes, blood pH, PCO2, PO2 or
metabolic parameters in comparison to the normoxic
control group could be detected.
Infusion of citrate at any concentration did not change
pre-ischemic values of any parameter other than sodium.
Sodium levels were higher, but still within the physio-
logical range, in the 0.6 mmol/kg/h and 1.0 mmol/kg/h
citrate groups at some time points compared to the I/R
control group with a maximum deviation of means of
4.5 mmol/l. Sodium levels showed no significant differences
in the follow-up study despite infusion of concentrated
NaCl. In the 1.0 mmol/kg/h citrate group and chloride with
a baseline value of 112.1 mmol/l was decreased at the end
of the reperfusion period (115.2 ± 0.8 mmol/l vs. 109.7 ±
1.2 mmol/l; p < 0.01 vs. I/R control group) (Table 1 and
Additional file 1: Figure S1). Base excess was significantly
lower in this group after 60 min of reperfusion (−6.9 ± 0.6
vs. −3.7 ± 0.4; p < 0.01 vs. I/R control group) with no
differences being detectable at the end of the experimental
procedure (Table 1).
Ionized calcium levels after acclimation ranged between
1.00 and 1.71 mmol/l with a mean of 1.45 ± 0.13 mmol/l.
The lowest ionized calcium level observed during the ex-
perimental procedure was 1.09 mmol/l (1.0 mmol/kg/h
citrate group; 1 h of reperfusion), while the highest level
observed was 1.68 mmol/l (1.0 mmol/kg/h citrate group;
3 h of reperfusion). Ionized calcium levels were temporar-
ily lower in the 1.0 mmol/kg/h citrate group following the
periods of citrate infusion, but stayed within the baseline
range (Fig. 7). Prior experiments in normoxic animals
showed that no effects on hemodynamics or any of the
measured serum parameters could be detected as long as
ionized calcium levels were kept above 1 mmol/l (data not
shown).
Effects of citrate on urine output
Urine output averaged 8.1 ± 1.3 μl/min in the normoxic
control group and was stable throughout the experiment.
Inter-individual differences ranged from 3 to 17 μl/min
A
B
Fig. 5 Number of bolus injections used to help support blood
pressure. Rats of the I/R control group and all citrate groups were
subjected to clamping of both renal vascular pedicles for 40 min
followed by three hours of reperfusion as diagrammed in Fig. 1.
Animals of the citrate groups received sodium citrate at indicated
concentrations 60 min before and 45 min after ischemia. Calcium
levels were kept stable by corresponding infusions of calcium
gluconate. Normoxic and I/R control groups received only 0.9% NaCl
solution. Infusion volume was 5 ml/kg/h in all animals. Additional
bolus injections of 0.5 ml 0.9% NaCl were administered repetitively
up to a maximum volume of 5 ml/kg/h at a mean arterial blood
pressure below 70 mmHg for more than 5 min. Box plots with
whiskers indicating minimum and maximum, six rats per group. a Bolus
injections during ischemia. # p< 0.05 and ## p< 0.01 vs. normoxic
control group. ** p< 0.01 vs. I/R control group. b Bolus injections during
reperfusion. # p < 0.05 and ### p < 0.001 vs. normoxic control
group. * p < 0.05 and ** p < 0.01 vs. I/R control group. 1 Bolus
injection = 0.5 ml 0.9% NaCl
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(Additional file 2: Figure S2A) and did not correlate
with time of measurement. I/R did not have a signifi-
cant effect on the mean values compared to the nor-
moxic control group. However, following ischemia half
of the animals developed a decrease in urine output
while the others became polyuric [1 μl/min vs. 27 μl/min]
(Additional file 2: Figure S2B). Infusion of citrate did
not change this pattern compared to the I/R control
group.
Citrate levels in plasma and urine
Citrate levels in plasma were measured 30 min after
catheter insertion, immediately before induction of is-
chemia after administration of the first citrate dose, at
the end of 40 min of ischemia and at 180 min of reper-
fusion. In the normoxic control group citrate levels in
plasma decreased slightly during the course of the ex-
periment (197 ± 17 vs. 136 ± 5 μmol/l; p < 0.05). Ischemia
tended to increase plasma citrate levels, but did not
Fig. 6 Mean arterial blood pressure in the follow-up study. The follow-up study using the same design as the initial study (see Fig. 1) was conducted
to control for the citrate-independent effects of the sodium load that accompanies citrate. Mean arterial blood pressure was assessed every 10 min
starting with the beginning of the surgical procedure. Arterial blood pressure was continuously recorded via a catheter placed in the femoral artery.
Grey-shaded areas indicate the periods of infusion of trisodium citrate or 3.5% NaCl. Calcium levels were kept stable by corresponding infusions of
calcium gluconate. Normoxic and I/R control groups received only 0.9% NaCl solution. Infusion volume was 5 ml/kg/h in all animals. Values
are means of 3–4 rats for the normoxic and I/R control groups and 6 rats per group for the 1.0 mmol/kg/h citrate and 3.0 mmol/kg/h Na+
groups. + p < 0.05 vs. 1.0 mmol/kg/h citrate group














pH 7.36 + 0.02 7.36 + 0.03 7.31 + 0.02 7.28 + 0.01## 7.31 + 0.01 7.27 + 0.02##
Base excess
[mmol/l]
−0.0 + 0.5 −1.0 + 0.3 −4.8 + 0.5### −4.2 + 1.0## −3.8 + 0.9## −5.4 + 0.5###
pCO2 [mmHg] 45.2 + 1.8 43.9 + 3.9 42.0 + 2.2 47.3 + 2.4 43.9 + 2.2 46.2 + 3.4
pO2 [mmHg] 437.5 + 12.7 446.7 + 10.0 452.2 + 12.8 444.7 + 11.5 439.3 + 5.9 437.2 + 12.0
K+ [mmol/l] 5.1 + 0.1 4.4 + 0.1 6.1 + 0.1### 6.4 + 0.1### 6.0 + 0.1### 5.8 + 0.1###
Cl-[mmol/l] 111 + 1 114 + 1 115 + 1 113 + 2 112 + 2 110 + 1**
Na+ [mmol/l] 139 + 1 141 + 1 140 + 1 139 + 1 141 + 0 143 + 1**
Glucose [mg/dl] 172 + 14 136 + 5 150 + 6 162 + 26 135 + 9 126 + 12
Lactate [mmol/l] 0.97 + 0.13 0.72 + 0.05 0.68 + 0.07 0.63 + 0.05 0.65 + 0.03 0.62 + 0.08
Values are means ± SE; n = 6 per group. Baseline values were obtained from the normoxic control group after the acclimation period; these values were not
significantly different from the baseline values of the other experimental groups. The other values were assessed from the last blood sampling at the end of the
full ischemia/reperfusion period. For experimental details, see Fig. 1
## p < 0.01 and ### p < 0.001 vs. normoxic control group. ** p < 0.01 vs. I/R control group
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reach significance (Fig. 8a). Citrate infusion increased
pre-ischemic citrate levels in plasma compared to the
I/R control group.
In the normoxic control group citrate levels in urine
did not change during the course of the experiment. Cit-
rate excretion in the I/R control group did not differ
from the normoxic control group during any of the indi-
cated time spans (Fig. 8b). Pre-ischemic citrate infusion
increased urinary citrate levels in a dose dependent fash-
ion reaching significance in the 0.6 mmol/kg/h (p < 0.01)
and 1.0 mmol/kg/h (p < 0.001) citrate groups compared
to the I/R control group. The second, post-ischemic
citrate infusion did not significantly increase urinary cit-
rate levels and levels had equalized in all groups by the
end of reperfusion.
Effects of citrate on osmolality
Blood for determination of osmolality was drawn in an
additional experiment that compared an I/R control
group and I/R 1.0 mmol/kg/h citrate group as described
above.
After 60 min of citrate infusion at a rate of 1.0 mmol/
kg/h plasma osmolality directly measured by cryoscopy
was not different from the plasma osmolality of the I/R
Fig. 7 Ionized plasma calcium levels. Box plots with whiskers indicating minimum and maximum, six rats per group. # p < 0.05, ## p < 0.01 and
### p < 0.001 vs. normoxic control group. ** p < 0.01 vs. I/R control group
A
B
Fig. 8 Plasma and urine citrate levels. Box plots with whishers indicating minimum and maximum, 4–6 rats per group. a Plasma citrate levels
measured at indicated time points. # p < 0.05 and ### p < 0.001 vs. normoxic control group. * p < 0.05 and *** p < 0.001 vs. I/R control group.
b Urine citrate levels measured in samples collected during the indicated time periods. # p < 0.05 and ### p < 0.001 vs. normoxic control group. **
p < 0.01 and *** p < 0.001 vs. I/R control group
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control group (301 ± 0.3 mosmol/kg vs. 303 ± 4 mosmol/
kg), nor could any difference be detected after 100 min of
reperfusion where MAP of the 1.0 mmol/kg/h citrate
group peaked (304 ± 4 mosmol/kg vs 306 ± 4 mosmol/kg).
Discussion
Intravenous infusion of 1.0 mmol/kg/h trisodium citrate
in a rat model of AKI (40 min ischemia, 180 min reper-
fusion) showed protective effects resulting in a small but
robust amelioration of increased pCrea and LDH levels
and a tendency for higher tissue ATP content. Intraven-
ous infusion of trisodium citrate was accompanied by a
concentration-dependent improvement of hemodynamic
stability during bilateral renal ischemia. A follow-up study
conducted to control for effects of the Na+ load going
along with citrate confirmed that the protective effects
were citrate-dependent.
In humans as well as in rodents trisodium citrate is
converted to citric acid which is metabolized in the citric
acid cycle at high rates mainly in the liver and to a small
percentage also in other organs such as skeletal muscle
and kidney [18]. Complete metabolism results in degrad-
ation to carbon dioxide and water. As hydrogen is con-
sumed during this process blood pH increases with the
potential risk of metabolic alkalosis. On the other hand,
an insufficient metabolism might result in citrate accu-
mulation and acidosis. With degradation of citrate the
chelated calcium is liberated again.
Citrate is nowadays frequently used for regional antic-
oagulation where it reduces bleeding risks and appeared
particularly beneficial after surgery, in sepsis and severe
multiple organ failure showing a positive impact on
morbidity, mortality and renal recovery possibly due to
interference with inflammation [9]. Additive effects such
as reduction of oxidative stress and inflammation have
also been reported [11]. Addition of citrate as a citric
acid cycle metabolite during reoxygenation of hypoxic
proximal renal tubules previously exposed to ischemia
improves energetic function and recovery probably by
driving substrate-level phosphorylation and decreasing
accumulated non-esterified fatty acids [12, 13]. Reduc-
tion of the mitochondrial and thereby cellular damage
during ischemia and early reoxygenation should possibly
enhance cellular resistance to subsequent damage in-
duced by oxygen radical formation and inflammatory re-
actions occurring in the later course of reperfusion.
To the best of our knowledge, direct renal protection
from I/R-induced renal injury by intravenous citrate has
not been studied previously.
No adverse effects following citrate infusion were ob-
served in the present study. Ionized calcium levels re-
quired for hemodynamic stability were kept within the
physiological range [19, 20] by infusion of 10% calcium
gluconate at fixed rates.
We utilized a novel intensive monitoring protocol that
can uncover central hemodynamic alterations contributing
to injury. As observed before, bilateral renal clamping
leads to a drop in MAP in our rat model of I/R-induced
AKI [14] that persists despite the use of bolus injections of
saline to compensate. Induction of hypotension is only
observed in bilateral and not in unilateral atraumatic
clamping in our model (data not shown). A significant
decrease in blood pressure associated with bilateral
(and not unilateral) renal ischemia has been described
before [21], although to our knowledge studies performing
close continuous arterial blood pressure monitoring es-
pecially during the clamping period are missing. The
mechanism involved in induction of hypotension dur-
ing bilateral renal clamping remain unclear, but it is
conceivable that this effect is related to interference by
the clamping itself with sympathetic nerves surround-
ing the renal artery, an effect similar to that seen with
renal denervation. Pre-ischemic infusion of citrate had
no immediate effect on MAP. However, infusion of citrate
prevented the drop in blood pressure during renal clamp-
ing reaching statistical significance in the 1.0 mmol/kg/h
citrate group in which MAP also tended to be higher dur-
ing most of the reperfusion period. The stabilizing effect
on blood pressure was accompanied by fewer bolus injec-
tions and cannot be explained by intravenous application
of a hyperosmotic solution as changes in plasma osmo-
lality were neither detected by blood gas analysis nor
by cryoscopy and observed effects could not be repro-
duced by infusion of hyperosmotic NaCl solution at the
same volumes.
Application of NaCl 0.9% has been identified as crit-
ical. Negative effects of NaCl 0.9% are ascribed to its un-
physiologically high chloride content. The high chloride
content is associated with an increased risk of hyper-
chloraemic metabolic acidosis [22–25] and animal stud-
ies have suggested that it is the critical determinant for
changes in renal blood flow, mediated primarily by ef-
fects on afferent and intrarenal arterial vessels [26–29].
Chloride levels of the 1.0 mmol/kg/h citrate group were
significantly different compared to the I/R control group
only after 3 h of reperfusion, but of questionable physio-
logical implication. In addition, pH was lowest in the
1.0 mmol/kg/h citrate group. Considering the only slight
changes in chloride levels and the missing signs of
(hyperchloraemic) metabolic acidosis in the groups re-
ceiving NaCl 0.9%, it seems very unlikely that observed
effects of citrate can simply be ascribed to a reduced ap-
plication of NaCl 0.9% in the 1.0 mmol/kg/h citrate
group.
Ionized calcium levels observed during the experimen-
tal period were never outside the baseline range. It is un-
likely that reduced ionized calcium levels as observed in
the 1.0 mmol/kg/h citrate group at time points before
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and after ischemia had any beneficial effects. In addition,
ionized calcium levels were not different during ischemia
in all groups when differences in blood pressure occurred
between groups. Minor, although significant differences
observed at other time points were not accompanied by
hemodynamic distinctions.
Even before induction of ischemia urine output was
very variable. Variability increased after induction of ische-
mia ranging from anuria to polyuria. Urine output was not
correlated to changes in pCrea, LDH concentrations or
tissue ATP content. Clamping of the renal pedicle should
convey a homogeneous burden of injury to all animals.
Temporary polyuria as a sign of tubular malfunction sec-
ondarily turning into oliguria/anuria has been described in
rats [30] and is a common feature in (human) patients,
too. Urine output is an observational parameter only.
Although oliguric AKI has a worse prognosis than non-
oliguric AKI [31], it is unclear in how far urine output
directly following hypoxia might reflect the severity of
renal injury or differences of such.
Since citrate is delivered as trisodium citrate, infusion
of each molecule of citrate is accompanied by three ions
of sodium. Therefore, the 1.0 mmol/kg/h citrate group
received 3.0 mmol/kg/h sodium during 60 min prior and
45 min post ischemia compared to 0.77 mmol/kg/h in
animals infused with NaCl 0.9%. There is a possibility
that the extra sodium increases intravascular volume
and thereby favors better early reperfusion and intratub-
ular solute flow with amelioration of I/R-induced injury.
Changes in plasma sodium levels did not strictly correl-
ate with citrate infusion periods and were minimal. In
addition, 60 min of citrate infusion before renal clamp-
ing did not result in increased blood pressure making
large changes of intravascular volume due to sodium
load less likely. Nevertheless, a follow-up study conducted
to control for high sodium load accompanied by infusion
of citrate confirmed that protective effects were produced
by citrate rather than by sodium. Further increase of cit-
rate delivery to 1.5 mmol/kg/h did not result in additional
improvement (data not shown).
Baseline citrate levels in plasma were in the range of
those observed for adult Sprague Dawley rats [32]. Ische-
mia itself tended to increase plasma citrate concentrations
compared to the normoxic control group, while citrate
infusions resulted in pre-ischemic elevated plasma cit-
rate levels which seemed to saturate at maximum con-
centrations of about 600 μmol/l. The infused citrate
increased urinary excretion indicating substantial de-
livery to the kidney, but underwent rapid extrarenal
metabolism and clearance as indicated both by the sat-
uration during infusion and the sharp decrease of
plasma citrate during the ischemia clamp period when
citrate was not being infused and could not be cleared
by the kidneys.
Urinary citrate excretion was increased in all animals
receiving citrate during the pre-ischemic period com-
pared to the normoxic and ischemia control groups
reaching maximum urinary levels of approximately
220 mmol/l in the 0.6 and 1.0 mmol/kg/h citrate groups.
At the end of the experiment plasma citrate levels of the
citrate-infused animals were no different from the levels
of the I/R control group and post-ischemia citrate excre-
tion did also not differ between groups.
An ischemia-induced increase in citrate has been dem-
onstrated after myocardial ischemia in the porcine heart,
where it was suggested to inhibit glycolysis and thereby
reduce the heart’s ability to compensate for energetic
deficiency [33]. Because of changes in myocardial net
release, citrate has been discussed as a potential marker
of myocardial ischemia [34]. As citrate is freely filtered
by the glomeruli, urinary citrate excretion is mainly influ-
enced by the rate of proximal tubular citrate reabsorption
through a Na+/citrate transporter located in the apical
membrane [35, 36]. Urinary citrate excretion has been
identified as a marker of favorable outcome after auto-
transplantation of kidneys following cold storage in pigs
[35]. It was suggested that a reduction in urinary citrate
excretion is due to the impairment of oxidative energy
metabolism promoted by I/R-injury. In our model urinary
citrate excretion is primarily determined by infused citrate.
Nevertheless, a reduction of urinary citrate might indicate
a lack of its production in the citric acid cycle and sup-
plementation of citrate can help to restore metabolic
function.
Pre-ischemic enhanced glomerular filtered citrate
reabsorbed by the proximal tubules representing the vul-
nerable site of the kidney may increase the intra-tubular
citrate concentration and offer benefit by driving
substrate-level phosphorylation for anaerobic ATP pro-
duction during the reperfusion period. Inhibition of gly-
colysis by citrate as opposed to myocardial cells [33] is
not an issue in renal proximal tubular cells which have
very little glycolytic capacity [37]. Citrate supplementation
of isolated proximal tubular cells during hypoxia and reox-
ygenation, but not during hypoxia alone, improved mito-
chondrial membrane potential and ATP levels. Under
aerobic conditions, as present during reoxygenation, cit-
rate may promote forward operation of the citric acid
cycle resulting in α-ketoglutarate production to drive the
substrate-level phosphorylation rescue pathway. Direct ap-
plication of α-ketoglutarate showed adverse effects in our
model as systemic effects on hemodynamics compete with
tubular effects [14].
Hemodynamic stabilization during ischemia by citrate
could improve outcome by favoring early reperfusion and
limiting the important damage that occurs at that time. It
is notable in this regard, that α-ketoglutarate/malate in
our prior study of this type worsened hypotension during
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ischemia and did not show the protection seen with citrate
even though it protects isolated tubules better than citrate
and, unlike citrate, is effective when administered to them
during hypoxia only [12, 14].
Citrate infusion in our rat model of I/R-induced AKI
did not affect the histological changes seen at the 3 h re-
perfusion time point studied. However, these changes in
the outer cortex are known to be highly reversible and
do not allow any conclusions with regard to the more
severe outer medullary damage that only develops later
(at least 6–12 h following the initial event) and is prob-
ably more functionally significant. Information about
structural protection is, therefore, limited by the time
frame of the model.
Patients afflicted by AKI especially in the intensive
care setting are often exposed to many, repeated and/or
ongoing incidences of damage (drops in blood pressure,
toxic events, etc.). Apart from renal replacement ther-
apy, where currently used concentrations might be too
low, citrate could be considered as a protective agent it-
self. It is unclear, if supplementation of citrate after is-
chemia only provides any protective effect as this was
not tested in our experimental setting. In clinical settings
involving continuous renal replacement therapy citrate
could be protective in cases of repeated and/or ongoing
incidences of damage.
Conclusions
In summary, we have applied a novel approach with in-
tensive biomonitoring to study the effects of sodium cit-
rate infusion with calcium support on I/R-induced AKI.
Citrate itself was well tolerated, appeared in the urine,
and also underwent rapid extrarenal metabolism. Citrate
infusion at 1.0 mmol/kg/h showed renal protection during
the early post-ischemic phase. This effect may derive both
from the benefits of citrate for tubule cell metabolism that
have previously been observed in isolated tubules as well as
from citrate-associated prevention of systemic hypotension
that occurs during the ischemic period. The data support
the rationale for further investigation of citrate infusion as a
therapeutic modality.
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